Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates that Co. is developing includes: ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; and ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, for the treatment of moderate to severe atopic dermatitis. Co. is also developing ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. The ACRS stock yearly return is shown above.
The yearly return on the ACRS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACRS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|